TwinBeech Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

TwinBeech Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-299,229	Closed	-$16.4M	–	581
2025 Q2	$16.4M	Buy	+299,229	New	+$17.6M	0.37%	80
2024 Q4	–	Sell	-320,287	Closed	-$22.5M	–	632
2024 Q3	$22.5M	Buy	+320,287	New	+$26.8M	0.43%	60
2023 Q1	–	Sell	-100,053	Closed	-$10.4M	–	625
2022 Q4	$10.4M	Sell	100,053 -61,870	-38%	-$5.81M	0.2%	146
2022 Q3	$13.7M	Buy	+161,923	New	+$14.4M	0.36%	88
2021 Q2	–	Sell	-15,874	Closed	-$1.2M	–	455
2021 Q1	$1.2M	Buy	15,874 +8,900	+128%	+$727K	0.18%	171
2020 Q4	$612K	Buy	+6,974	New	+$553K	0.1%	259

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

TwinBeech Capital's BMRN Position: Q3 2025 in Review

TwinBeech Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 299,229 shares — an estimated $16.4M sold.

TwinBeech Capital first reported a position in BMRN in Q4 2020 and held it in 6 quarters. The position peaked at $22.5M in Q3 2024. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

TwinBeech Capital reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
TwinBeech Capital sold 299,229 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $16.4M.
TwinBeech Capital first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 6 quarters.
TwinBeech Capital's BioMarin Pharmaceuticals position peaked at $22.5M in Q3 2024.
576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on TwinBeech Capital's 13F filing for Q3 2025, filed 14 Nov 2025.